JP2016507521A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507521A5
JP2016507521A5 JP2015555498A JP2015555498A JP2016507521A5 JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5 JP 2015555498 A JP2015555498 A JP 2015555498A JP 2015555498 A JP2015555498 A JP 2015555498A JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
sequence shown
disease
motomeko
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507521A (ja
JP6539585B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000066 external-priority patent/WO2014117220A1/en
Publication of JP2016507521A publication Critical patent/JP2016507521A/ja
Publication of JP2016507521A5 publication Critical patent/JP2016507521A5/ja
Application granted granted Critical
Publication of JP6539585B2 publication Critical patent/JP6539585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555498A 2013-02-01 2014-01-31 抗cd83抗体及びその使用 Expired - Fee Related JP6539585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759780P 2013-02-01 2013-02-01
US61/759,780 2013-02-01
PCT/AU2014/000066 WO2014117220A1 (en) 2013-02-01 2014-01-31 Anti-cd83 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019000340A Division JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2016507521A JP2016507521A (ja) 2016-03-10
JP2016507521A5 true JP2016507521A5 (enExample) 2017-02-23
JP6539585B2 JP6539585B2 (ja) 2019-07-03

Family

ID=51261317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555498A Expired - Fee Related JP6539585B2 (ja) 2013-02-01 2014-01-31 抗cd83抗体及びその使用
JP2019000340A Pending JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019000340A Pending JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Country Status (13)

Country Link
US (3) US9840559B2 (enExample)
EP (2) EP2951208B1 (enExample)
JP (2) JP6539585B2 (enExample)
KR (2) KR102204127B1 (enExample)
CN (1) CN105531289B (enExample)
AU (1) AU2014213009B2 (enExample)
CA (1) CA2899960C (enExample)
DK (1) DK2951208T3 (enExample)
ES (1) ES2762622T3 (enExample)
MX (1) MX2015010023A (enExample)
NZ (1) NZ711543A (enExample)
PT (1) PT2951208T (enExample)
WO (1) WO2014117220A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014213009B2 (en) * 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
AU2015336931B2 (en) * 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
KR20200066613A (ko) * 2017-09-13 2020-06-10 키라 바이오테크 피티와이 리미티드 치료 방법
US12492254B2 (en) * 2018-02-23 2025-12-09 H. Lee Moffitt Cancer Center and Research Intitute. Inc. CD83-binding chimeric antigen receptors
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
EP4013447A4 (en) * 2019-08-16 2024-05-29 H. Lee Moffitt Cancer Center & Research Institute, Inc. T CELLS EXPRESSING A CHIMERIC ANTI-CD83 ANTIGEN RECEPTOR
EP4674865A3 (en) * 2021-03-09 2026-03-25 GI Innovation, Inc. Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor
WO2022260909A1 (en) * 2021-06-09 2022-12-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods of using anti-cd83 chimeric antigen receptor expressing t cells
CN117547553A (zh) * 2023-11-21 2024-02-13 中国人民解放军陆军特色医学中心 Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用
CN121975013A (zh) * 2026-04-09 2026-05-05 天津旷博同生生物技术有限公司 一种抗人cd83抗体及应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0302894B1 (en) 1986-04-28 1992-11-19 Endotronics Inc. Method of culturing leukocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0009772A (pt) * 1999-04-14 2002-01-08 Us Health Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP4264348B2 (ja) 2001-08-20 2009-05-13 プロテオム システムズ リミテッド 診断検査方法および装置
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466845A1 (en) * 2001-11-21 2003-06-05 Fred Ramsdell Manipulation of cytokine levels using cd83 gene products
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
EP1572976B1 (en) * 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulating immune responses
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8420783B2 (en) * 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
CA2602709A1 (en) 2005-03-31 2006-10-05 Telethon Institute For Child Health Research Isolation of inhibitor of ires-mediated translation
AU2006249640C1 (en) * 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
WO2007019620A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US8197809B2 (en) 2008-06-25 2012-06-12 Korea Research Institute Of Bioscience And Biotechnology CD9-specific human antibodies
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
AU2015336931B2 (en) 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
KR20200066613A (ko) 2017-09-13 2020-06-10 키라 바이오테크 피티와이 리미티드 치료 방법

Similar Documents

Publication Publication Date Title
TWI883026B (zh) 抗dll3嵌合抗原受體及其用途
JP2022071087A (ja) 抗cd38抗体および使用方法
JP2023071684A (ja) 抗bcma重鎖のみ抗体
JP2012501670A5 (enExample)
CN112955470A (zh) 抗tnfr2抗体及其用途
CN109563170B (zh) 抗gitr抗体及其用途
TW201031421A (en) IL-1 binding proteins
JP2012501669A5 (enExample)
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
JP2012526558A5 (enExample)
KR20180083944A (ko) 항체 및 이의 사용 방법
TW201134487A (en) Therapeutic DLL4 binding proteins
JP7796034B2 (ja) ヒトcd45rcに特異的なキメラ抗原受容体およびその使用
US12071479B2 (en) Antibodies against ILT2 and use thereof
JP2017530119A (ja) リンパ球における阻害経路の中和
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
KR20120104542A (ko) Il?1 결합 단백질
CN101512008A (zh) 白介素-13结合蛋白
AU2020328931A1 (en) Antibodies against ILT2 and use thereof
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
CN113278071B (zh) 抗人干扰素α受体1单克隆抗体及其应用
CA3188068A1 (en) Multispecific binding agents and uses thereof
CN109071660A (zh) 预防移植物抗宿主疾病的方法
WO2022031680A1 (en) Cd47 binding agents and uses thereof
US20230303699A1 (en) Pd-l1 binding agents and uses thereof